Evidence map›Paper›PMID 31222277›Full record

ArticleJournal of Crohn's & colitis2019

Erratum: Leucine-rich Alpha-2 Glycoprotein is a Serum Biomarker of Mucosal Healing in Ulcerative Colitis.

Shinichiro Shinzaki, Katsuyoshi Matsuoka, Hideki Iijima, Shinta Mizuno, Satoshi Serada, Minoru Fujimoto, Norimitsu Arai, Noriyuki Koyama, Eiichi Morii, Mamoru Watanabe and 4 more

Abstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of Crohn's & colitis, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors.

Shinichiro ShinzakiDepartment of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine, Osaka, Japan.
Katsuyoshi MatsuokaDepartment of Gastroenterology and Hepatology, Tokyo Medical and Dental University, Tokyo, Japan.
Hideki IijimaDepartment of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine, Osaka, Japan.
Shinta MizunoDepartment of Internal Medicine, Keio University School of Medicine, Tokyo, Japan.
Satoshi SeradaLaboratory of Immune Signal, National Institute of Biomedical Innovation, Health and Nutrition, Osaka, Japan.
Minoru FujimotoLaboratory of Immune Signal, National Institute of Biomedical Innovation, Health and Nutrition, Osaka, Japan.
Norimitsu AraiDepartment of Research and Development, EIDIA Co. Ltd, Tokyo, Japan.
Noriyuki KoyamaDepartment of Research and Development, EIDIA Co. Ltd, Tokyo, Japan.
Eiichi MoriiDepartment of Pathology, Osaka University Graduate School of Medicine, Osaka, Japan.
Mamoru WatanabeDepartment of Gastroenterology and Hepatology, Tokyo Medical and Dental University, Tokyo, Japan.
Toshifumi HibiCenter for Advanced IBD Research and Treatment, Kitasato University Kitasato Institute Hospital, Tokyo, Japan.
Takanori KanaiDepartment of Internal Medicine, Keio University School of Medicine, Tokyo, Japan.
Tetsuo TakeharaDepartment of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine, Osaka, Japan.
Tetsuji NakaLaboratory of Immune Signal, National Institute of Biomedical Innovation, Health and Nutrition, Osaka, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID31222277
PMCPMC6903787

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.